The Cheshire-headquartered business has announced its headline half-year figures, recording global revenue of £13.0m for the six months ending 30 September, a 19% rise on this time last year.
The group’s performance has been driven by continued underlying growth for its UK business alongside exceptional growth in the its international activity, notably the US, where revenues from Crawford’s North American subsidiary for the six month period increased by 136%.
Crawford’s international success has also been recognised and celebrated here domestically, with the group securing its first ever Queen’s Award for Enterprise (International Trade), as well as being named the UK’s largest SME wound care business.
CEO Richard Anderson said: “As anticipated, we’ve enjoyed a really strong first six months for 2016/17, and we are well set to exceed expectations for the full year.
“The success of our wound care brands – now entirely owned and developed by Crawford – goes to show the quality of the Life Sciences industry in Cheshire and the North West.
“Like many others in the region, we’re enjoying tremendous success overseas and showing how our IP can lead international thinking and practice in healthcare.
“For example, our proprietary silver-based OxysaltTM technology is enabling a number of our strategically important brands to compete with, and clinically beat, global leading brands.
“As a result, we’re challenging and outrunning huge international operators in some of world’s biggest product categories.”
Having enjoyed 41% average annual sales growth over the last three years, Crawford now employs over 130 people across its UK and international team.
Anderson concluded: “Developing and marketing truly unique products simply wouldn’t be possible without the team we have assembled and the sales approach we have adopted.
“These figures are testament to their endeavour, and long may the Crawford family continue to grow.”